Response to second line chemotherapy in ovarian cancer of epithelial origin
- 1 December 1981
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 17 (12), 1259-1262
- https://doi.org/10.1016/0014-2964(81)90005-0
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Second-line efficacy of intermediate high-dose methotrexate with citrovorum factor rescue + cyclophosphamide in ovarian cancerGynecologic Oncology, 1979
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978
- Hexamethylmelamine in alkylating agent-resistant ovarian carcinomaCancer, 1978
- Cancer of ovary in Israel (1966–1971)Gynecologic Oncology, 1978
- Melphalan vs polymelphalanum in ovarian cancer patients resistant to cyclophosphamide: A tentative statistical approach to balance risks and benefitsEuropean Journal of Cancer (1965), 1977
- Second trial drugs in ovarian cancerGynecologic Oncology, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- CHEMOTHERAPY FOR MUSTARD-RESISTANT OVARIAN ADENOCARCINOMA - RANDOMIZED TRIAL OF CCNU AND METHYL-CCNU1977
- TREATMENT OF ADVANCED OVARIAN CARCINOMA WITH HIGH-DOSE CYCLOPHOSPHAMIDE AFTER FAILURE ON MELPHALAN1977
- Chemotherapy in the treatment of cancer of the ovaryAmerican Journal of Obstetrics and Gynecology, 1970